Revenue Breakdown
Composition ()
No data
Revenue Streams
Integra Lifesciences Holdings Corp (IART) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Neurosurgery, accounting for 50.1% of total sales, equivalent to $201.56M. Other significant revenue streams include Wound Reconstruction and Care and Instruments. Understanding this composition is critical for investors evaluating how IART navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Integra Lifesciences Holdings Corp maintains a gross margin of 57.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.75%, while the net margin is -0.39%. These profitability ratios, combined with a Return on Equity (ROE) of -39.90%, provide a clear picture of how effectively IART converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IART competes directly with industry leaders such as CSTL and INMD. With a market capitalization of $812.89M, it holds a significant position in the sector. When comparing efficiency, IART's gross margin of 57.02% stands against CSTL's 76.33% and INMD's 78.28%. Such benchmarking helps identify whether Integra Lifesciences Holdings Corp is trading at a premium or discount relative to its financial performance.
